VRDN | Viridian Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	19.78 - 20.87
52 Week Range	11.40 - 27.20
Beta	1.09
Implied Volatility	91.98%
IV Rank	23.57%
Day's Volume	1,008,878
Average Volume	1,515,214
Shares Outstanding	79,212,700
Market Cap	1,567,619,333
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-06-18

Valuation
Profitability
Growth
Health
P/E Ratio	-4.58
Forward P/E Ratio	-7.12
EPS	-4.32
1YR Price Target	40.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	94
Country	USA
Website	VRDN

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

VRDN's peers: ALDX, CRNX, HALO, HRMY, HUMA, IMCR, INBX, JAZZ, KALV, KURA, LGND, MRSN, NUVL, PCVX, PLRX, PRTA, RCKT, ROIV, RYTM, SNDX, VCYT, DICE, ACLX, CYTK, GPCR, ICVX, RVMD, INZY, TERN, BPMC, ETNB, PTGX, MRUS, REPL, CERE, XENE, XNCR

*Chart delayed

Analyzing fundamentals for VRDN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong. For more detailed analysis please see VRDN Fundamentals page.

Watching at VRDN technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on VRDN Technicals page.